year
old
man
histori
idiopath
pannicul
longterm
steroid
treatment
present
hospit
month
histori
dyspnea
malais
nausea
vomit
hypotens
tachycard
acut
kidney
injuri
prior
present
hospit
week
nearbi
hospit
similar
symptom
found
multifoc
ground
glass
opac
ct
chest
condit
admiss
improv
fluid
resuscit
stressdos
steroid
treatment
presum
sepsi
infecti
rheumatolog
workup
neg
note
bilater
pulmonari
infiltr
fig
b
one
week
discharg
howev
present
system
inflammatori
respons
syndrom
sir
bronchoscopi
reveal
acut
chronic
organ
pneumonia
evid
infect
bone
marrow
biopsi
perform
demonstr
hypercellular
marrow
puls
dose
steroid
initi
organ
pneumonia
improv
significantli
next
week
continu
empir
antimicrobi
taper
steroid
week
regimen
howev
decompens
hypoxia
hypotens
worsen
infiltr
note
chest
radiograph
fig
ferritin
elev
ngml
elev
uml
trigylcerid
normal
fibrinogen
elev
given
unremark
bone
marrow
biopsi
day
elev
fibrinogen
possibl
hemophagocyt
lymphohistiocytosi
hlh
dismiss
hyperferritinemia
elev
attribut
histori
blood
transfus
occult
infect
continu
improv
empir
antimicrobi
steroid
discharg
hospit
day
admiss
icu
complet
cours
levofloxacin
mg
prednison
daili
present
hospit
third
time
day
discharg
hypotens
hypoxia
requir
endotrach
intub
vasopressor
antibiot
steroid
restart
admit
icu
pulmonari
statu
rapidli
improv
day
howev
decompens
hypotens
elev
lactat
receiv
intraven
fluid
intraven
steroid
given
unclear
associ
chang
antimicrobi
regimen
steroid
dose
clinic
condit
steroid
dose
decreas
mg
prednison
daili
mg
day
repeat
bone
marrow
biopsi
perform
show
rare
hemophagocyt
macrophag
evid
malign
next
day
set
reduc
steroid
dose
episod
hypoxia
hypotens
ferritin
measur
time
ngml
increas
ngml
day
fig
measur
elev
uml
diagnosi
hlh
made
start
chemotherapi
etoposid
high
dose
dexamethason
eight
week
elaps
sinc
initi
present
patient
initi
etoposid
dexamethason
without
cyclosporin
per
protocol
rapidli
improv
move
hematologyoncolog
ward
cours
complic
recurr
fever
rise
ferritin
addit
filgrastim
regimen
week
therapi
discontinu
improv
uniformli
month
transfer
physic
medicin
servic
rehabilit
subsequ
discharg
home
continu
well
month
diagnosi
prepar
allogen
bone
marrow
transplant
time
adult
hlh
often
presentswith
dramat
nonspecif
featur
includ
fever
organomegali
cytopenia
kidney
injuri
alter
mental
statu
mani
patient
hlh
present
sever
coagul
disord
includ
dissemin
intravascular
coagul
hypofibrinoginemia
mani
associ
sever
bleed
illustr
case
experi
rapid
fluctuat
hemodynam
instabl
hypox
respiratori
failur
also
common
featur
result
abnorm
inflammatori
respons
present
symptom
laboratori
find
overlap
significantlywith
sever
sepsi
uncommon
adult
patient
hlh
recent
hospit
presum
sepsi
hlh
entertain
diagnosi
one
unexplain
relaps
import
step
recogn
hlh
critic
ill
patient
therefor
consid
differenti
diagnosi
alongsid
common
caus
shock
respiratori
failur
primari
hlh
geneticdisord
may
diagnos
molecular
test
suggest
famili
histori
clinic
present
secondari
hlh
clinic
syndrom
divers
caus
diagnost
criteria
hlh
current
base
select
criteria
trial
enrol
pediatr
patient
tabl
presenc
fever
organomegali
cytopenia
hypertriglyceridemia
hypofibrinogenemia
nonspecif
wide
accept
help
criteria
defin
syndrom
presenc
hemophagocytosi
despit
lend
hlh
name
also
nonspecif
search
appropri
biomark
remain
area
activ
import
investig
detail
practic
critic
inform
lead
diagnosi
hlh
isoften
deriv
follow
patient
sever
day
observ
respons
lack
thereof
treatment
sepsi
common
condit
relationship
biomark
patient
evolv
clinic
condit
largest
trial
hlhtreatment
trial
investig
treatment
hlh
etoposid
dexamethason
cyclosporin
children
adolesc
longterm
followup
trial
suggest
intensifi
cyclosporin
regimen
addit
intrathec
steroid
reduc
time
hsct
improv
outcom
significantli
pediatr
popul
etoposid
dexamethason
becom
mainstay
treatment
adult
patient
hlh
antithymocyt
globulin
also
use
combin
steroid
cyclosporin
intrathec
chemotherapi
recent
consensu
review
malignancyassoci
hlh
suggest
tailor
treatment
underli
trigger
perform
statu
organ
function
addit
therapi
patient
receiv
earlyconsult
hematologist
center
experienc
treatment
hlh
critic
immunomodulatori
therapi
hlh
area
activ
investig
bone
marrow
transplant
consid
cur
therapi
patient
known
suspect
genet
caus
hlh
earli
therapi
hlh
may
limit
byendorgan
damag
present
time
diagnosi
especi
liver
kidney
injuri
highlight
case
present
treatment
high
dose
steroid
may
provid
adequ
tempor
therapi
allow
patient
stabil
ultim
receiv
definit
therapi
case
highlight
adultpati
icu
often
diagnos
hlh
sever
episod
appar
improv
follow
worsen
period
critic
ill
comprehens
longitudin
studi
cohort
patient
hlh
enrol
studi
exclus
studi
children
age
cohort
cumul
mortal
mortal
within
week
diagnosi
surviv
among
patient
underw
hsct
hlh
adult
far
like
secondari
hlh
pediatr
popul
though
late
present
primari
hlh
possibl
among
critic
ill
patient
receiv
etoposid
treatment
hlh
near
surviv
rate
report
multicent
sevenyear
seri
adult
hlh
case
describ
median
overal
surviv
month
surviv
discharg
manyadult
cohort
mirror
pediatr
popul
longterm
mortal
secondari
hlh
may
reflect
underli
malign
shortterm
mortalityfrom
hlh
depend
strongli
local
treatment
resourc
support
care
vari
wide
among
singlecent
studi
nearli
prior
discharg
across
center
howev
hlh
relat
malign
found
highest
mortal
follow
autoimmun
infecti
caus
singl
center
descript
studi
worst
prognosi
found
patient
malign
associ
hlh
extrem
hyperferritinemia
median
surviv
month
north
american
tertiari
care
center
patient
hlh
secondari
caus
malign
median
surviv
month
compar
less
month
case
associ
malign
sever
ill
time
diagnosi
hlh
also
appear
bear
outcom
despit
treatment
thrombocytopenia
mark
hyperferritinemia
shock
icu
admiss
associ
mortal
singl
center
studi
patient
hlh
multivari
analys
age
lymphoma
decreas
platelet
count
etoposid
administ
part
oftreat
associ
increas
mortal
highlight
inth
case
present
diagnosi
hlh
often
difficult
delay
multipl
condit
share
least
sever
diagnost
criteria
hlh
genet
test
propos
mean
improv
diagnosi
therefor
treatment
hlh
use
highthroughput
sequenc
strategi
gene
link
hlh
research
develop
screen
test
sensit
detect
known
genet
mutat
hlh
howev
util
prospect
cohort
adult
hlh
patient
patient
identifi
mutat
highlight
lack
clear
genet
caus
adult
hlh
specif
biomark
hlh
would
like
shorten
time
diagnosi
therapi
bone
marrow
hemophagocytosi
lend
name
hlh
neither
sensit
specif
disord
nk
cell
activ
level
part
hlh
diagnost
criteria
theselaboratori
studi
avail
refer
laboratori
ideal
biomark
test
would
reli
commonli
rapidli
avail
assay
determin
ferritin
level
pediatr
popul
hyperferritinemia
mcgl
greater
specif
hlh
howev
recent
retrospect
studi
demonstr
hlh
diagnos
adult
children
ferritin
mcgl
suggest
biomark
less
specif
previous
thought
patient
diagnos
hlh
ferritin
level
reflect
diseas
cours
activ
children
mark
decreas
ferritin
portend
decreas
short
term
mortal
hlh
treatment
critic
ill
adult
howev
increas
preval
condit
elev
ferritin
infect
malign
autoimmun
diseas
liver
injuri
chronic
blood
transfus
make
hyperferritinemia
nonspecif
find
hlh
hospit
patient
elev
ferritin
level
ngml
diagnosi
hlh
patient
like
liver
injuri
infect
elev
ferritin
alon
addit
particular
caus
secondari
hlh
may
associ
variabl
biomark
pattern
exampl
hlh
due
tolymphoma
may
present
high
ratio
ferritin
compar
caus
given
hlh
disord
immun
dysregul
effort
made
differenti
hlh
infect
base
cytokin
pattern
pediatr
popul
whether
approach
fruit
adult
requir
studi
randomizedcontrol
trial
treatment
adult
hlh
treatment
regimen
adapt
studi
primarili
includ
children
trial
salvag
therapi
doxorubicinetoposidemethylprednisolon
adult
mostli
nonfamili
refractori
hlh
demonstr
overal
respons
rate
patient
surviv
undergo
diseas
specif
therapi
recent
case
seri
report
use
interleukin
antagonist
anakinra
steroid
ivig
eight
critic
ill
patient
hlh
demonstr
hospit
surviv
rate
addit
research
nonetoposid
base
treatment
regimen
may
therefor
warrant
critic
ill
patient
multipl
organ
failur
alemtuzumab
human
monoclon
antibodi
target
use
salvag
therapi
refractori
adult
hlh
evalu
part
ongo
clinic
trial
primari
therapi
combin
etoposid
clinicaltrialsgov
identifi
biolog
small
molecul
current
evalu
forvari
form
hlh
ruloxitnib
tocilizumab
emapalumab
hlh
associ
wide
varieti
primari
secondari
etiolog
sever
sepsislik
syndrom
identifi
specif
clinic
context
adult
ma
commonlyseen
rheumatolog
diseas
system
lupu
erythematosu
adult
onset
still
diseas
aosd
latter
character
clinic
quotidian
fever
arthralgia
salmonpink
skin
rash
sore
throat
lymphadenopathi
organomegali
nearli
half
masshlh
patient
critic
ill
requir
mechan
ventil
vasoact
support
clinic
masshlh
difficultto
diagnos
though
suspect
critic
ill
persist
febril
patient
suggest
diagnost
criteria
ma
complic
sjia
criteria
ma
adult
rheumatolog
diseas
recent
variabl
score
system
hscore
develop
use
identifi
adult
shlh
tabl
hscore
correspondsto
sensit
specif
identifi
patient
shlh
treatment
beperform
consult
hematolog
expert
valid
approach
treatment
adult
patient
masshlh
foundat
treatment
high
dose
steroid
g
methylprednisolon
daili
day
although
mani
patient
may
requir
addit
therapi
use
receptor
antagonist
anakinra
shown
benefit
ma
associ
sjia
may
use
adult
masshlh
addit
therapi
includ
ivig
rituximab
ebv
associ
diseas
cyclosporin
macrophag
activationlik
syndrom
mal
describ
patient
sepsi
hscore
andor
evid
dissemin
intravascular
coagul
hepatobiliari
dysfunct
presenc
mal
wasassoci
increas
risk
death
within
first
day
sepsi
ferritin
level
ngml
associ
specif
mal
diagnosi
patient
interestingli
sepsi
patient
ma
featur
includ
hbddic
mortal
benefit
phase
iii
clinic
trial
use
anakinra
howev
util
treat
patient
sepsi
ma
featur
requir
valid
futur
clinic
trial
syndrom
character
byfev
hypotens
capillari
leak
neurotox
death
neurolog
side
effect
particularli
devast
includ
encephalopathi
aphasia
obtund
seizur
rate
cr
variabl
among
studi
rang
patient
develop
sever
symptom
develop
cr
associ
higher
tumor
burden
bone
marrow
blast
higher
dose
cart
cell
diagnost
criteria
cr
due
cart
cell
develop
tabl
gener
syndrom
suspectedin
patient
receiv
cart
therapi
develop
evid
fever
end
organ
damag
given
common
natur
side
effect
grade
scale
symptom
sever
treatment
algorithm
propos
institut
consid
icu
admiss
grade
toxic
requir
icu
admiss
grade
toxic
tabl
initi
studi
demonstr
efficaci
receptor
block
monoclon
antibodi
tocilizumab
sever
cr
relat
cart
cell
therapi
commonli
use
first
lineag
patient
symptom
includ
progress
hypoxia
hypotens
manag
usual
perform
context
establish
protocol
institut
administ
cart
therapi
clinic
patient
maypres
symptom
pneumonia
hypox
respiratori
failur
multilobar
infiltr
chest
imag
ip
usual
present
first
month
hematopoiet
cell
transplant
hct
though
later
present
day
posthct
also
report
histor
incid
tradit
myeloabl
condit
lower
modern
nonmyeloabl
regimen
one
retrospect
cohort
studi
median
time
onset
day
iqr
day
hct
twoyear
mortal
pathognomon
pattern
ofhistolog
alveolar
injuri
patient
rare
abl
toler
lung
biopsi
therefor
diagnosi
reli
exclus
etiolog
may
caus
multilobar
infiltr
respiratori
failur
bronchoalveolar
lavag
bal
perform
test
common
bacteri
includ
acidfast
bacilli
nocardia
legionella
nonbacteri
cmv
rsv
pcp
hsv
vzv
influenza
parainfluenza
human
metapneumoviru
rhinoviru
coronaviru
chlamydia
mycoplasma
aspergillu
organ
import
test
emphas
fact
bal
specimen
ip
patient
detect
bacteri
viral
pathogen
use
modern
techniqu
thu
lower
respiratori
tract
sampl
may
one
import
diagnost
intensivist
offer
reach
diagnosi
ip
patient
must
also
anabs
cardiac
dysfunct
acut
renal
failur
iatrogen
fluid
overload
contribut
pulmonari
dysfunct
current
treatment
ip
includessupport
care
hypox
respiratori
failur
system
corticosteroid
respons
rate
recent
clinic
trial
high
dose
steroid
median
time
respons
day
steroid
treatment
typic
mgkgday
methylprednisolon
equival
continu
intraven
three
day
subsequ
oral
dose
taper
day
bind
protein
etanercept
use
combin
steroid
demonstr
improv
respons
therapi
earli
surviv
small
singl
center
studi
phase
iii
clinic
trial
adult
ip
etanercept
provid
addit
benefit
steroid
alon
though
enrol
trial
prematur
end
definit
conclus
regard
use
etanercept
ip
made
trial
alon
notabl
etanercept
use
associ
withincreas
risk
opportunist
infect
malign
relaps
compar
placebo
control
venoven
extracorpor
membran
oxygen
use
report
earli
late
ip
though
efficaci
impact
outcom
unclear
patient
respond
steroid
therapi
treatment
also
unclear
elev
plasma
patient
ip
suggest
inhibitor
tocilizumab
may
benefit
treat
prevent
ip
sever
import
clinic
syndrom
includ
hlh
ma
ip
cr
mimic
sepsi
caus
critic
ill
immun
dysregul
absenc
infect
identif
syndrom
requir
high
index
suspicion
awar
clinic
context
risk
factor
well
care
exclus
infect
attent
respons
empir
therapi
prognosi
syndrom
often
uncertain
recent
evid
indic
patient
surviv
presenc
excel
support
care
strongli
driven
underli
diseas
rather
sepsislik
syndrom
